VCYT241220C22500
- 7.60
- 0.000.00%
Veracyte Newsroom
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
Express News | Veracyte Inc : Guggenheim Raises Target Price to $45 From $40
Those Who Invested in Veracyte (NASDAQ:VCYT) a Year Ago Are up 68%
If You Invested $1000 in Veracyte a Decade Ago, This Is How Much It'd Be Worth Now
Express News | Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in Nccn® Prostate Cancer Guidelines
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN Prostate Cancer Guidelines
Goldman Sachs Downgrades Veracyte(VCYT.US) to Hold Rating
Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37
Insider Sale: VP of $VCYT (VCYT) Sells 5,032 Shares
Veracyte, Inc. (NASDAQ:VCYT) Held Back By Insufficient Growth Even After Shares Climb 30%
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Veracyte Is Maintained at Underweight by Morgan Stanley
Veracyte Price Target Raised to $28.00/Share From $26.00 by Morgan Stanley
Express News | Veracyte Inc : Morgan Stanley Raises Target Price to $28 From $26
Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside
Wolfe Research Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $50
Veracyte Initiated With an Outperform at Wolfe on Growth, Margin Potential
Veracyte Initiated With an Outperform at Wolfe Research
Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing
ARKK's Holdings Ranked by SA Quant Grades